1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks

Abstract

Listen

Translate article

BackgroundThe pangenotypic direct-acting antivirals (DAAs) glecaprevir (developed by AbbVie and Enanta) coformulated with pibrentasvir (G/P) are approved as an 8-week regimen to treat chronic HCV infection for all six major genotypes (GT). An integrated analysis of patients treated with G/P for 8 weeks was performed to investigate factors impacting time to viral suppression, and whether lack of viral suppression by treatment week 4 was predictive of relapse.MethodsData were pooled from five phase 2 or 3 clinical studies, and included patients with HCV GT 1–6 infection without cirrhosis who were either treatment naïve or experienced with IFN or pegIFN with or without ribavirin (RBV) or sofosbuvir and RBV with or without pegIFN. G/P (300 mg/120 mg) was orally dosed once-daily for 8 weeks. Patients lost to follow-up or with missing SVR12 data (N = 13) were excluded from the analysis since the impact of viral suppression (HCV RNA below lower limit of quantification [LLOQ]) on response cannot be assessed in these patients. Two patients with on-treatment virologic failure were excluded since we sought to determine whether detectable HCV RNA at treatment week 4 was predictive of relapse.ResultsThe analysis included 950 patients; 63 (7%) were black, 171 (18%) had BMI ≥30, and 24% had baseline HCV RNA ≥6 million. The majority of patients were white, male, and HCV treatment-naïve. Among 942 patients with data, 906 (96%) had HCV RNA <LLOQ at treatment week 4, and of those, 899/906 (99%; 95% CI 98.4–99.6) achieved SVR12; additional results by subgroups are in Table 1. There was no common baseline factor more frequently observed among the seven patients who relapsed other than male sex (5/7; 71%). Of the 36 patients with HCV RNA >LLOQ at treatment week 4 (median baseline HCV RNA 6.7 log10 IU/mL; range 5.2–7.6 log10 IU/mL), 100% (95% CI 90.4–100.0) achieved SVR12.ConclusionIn patients treated with G/P for 8 weeks, failure to suppress HCV RNA by treatment week 4 was not predictive of treatment outcome, suggesting that treatment extension in patients eligible for 8-week regimens based on this milestone is not warranted. Data will also be presented for patients with compensated cirrhosis treated with 12 or 16 weeks of G/P. Disclosures C. Sarrazin, Abbott, AbbVie, BMS, Gilead, Janssen, Merck/MSD; Research Support: Abbott, Gilead, Janssen, Siemens: Board Member and Consultant, Consulting fee. Abbott, AbbVie, BMS, Gilead, Janssen, Merck/MSD, Roche, Siemens: Speaker’s Bureau, Speaker honorarium. T. Tran, AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck: Consultant, Grant Investigator and Research Contractor, Consulting fee, Research grant and Research support. D. Dylla, AbbVie, Inc.: Employee and Shareholder, Salary and Stock and/or options. J. J. Feld, AbbVie, Gilead, Janssen, Merck: Board Member, Consultant, Grant Investigator and Scientific Advisor, Consulting fee, Grant recipient and Research grant. S. Arora, Abbvie, Gilead: Grant Investigator and Research Contractor, Research grant and Research support. D. Victor III, AbbVie, Intercept: Investigator and Scientific Advisor, Consulting fee. Y. B. Hu, AbbVie Inc: Employee and Shareholder, Salary and Stock and/or options. S. Wang, AbbVie Inc.: Employee and Shareholder, Salary and Stock and/or options. F. Mensa, AbbVie Inc.: Employee and Shareholder, Salary and Stock and/or options. D. L. Wyles, AbbVie, Gilead, Merck, Tacere Therapeutics: Consultant, Grant Investigator, Research Contractor and Scientific Advisor, Consulting fee, Research grant and Research support.